KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027KT-621 BROADEN2 Phase 2b atopic dermatitis (AD) trial ...

Credit: Below the Sky / Shutterstock.com Two of Sanofi’s lunsekimig Phase II trials have met their primary endpoints in respiratory disease, while a study in atopic dermatitis failed to show benefit.

WILMINGTON, DE — Incyte (Nasdaq: INCY) reported 54-week Phase III data showing its experimental drug povorcitinib reduced ...

AstraZeneca shares were up about 3.5% Friday after the company said its drug for COPD, a deadly lung disease often caused by smoking, slowed patients' symptoms in two large trials. The drug, ...

For people with chronic obstructive pulmonary disease (COPD), characterized by cough and shortness of breath, Anoro Elipta (umeclidinium-vilanterol) may work better than other approved COPD ...

This presentation was given at the American Thoracic Society (ATS) International Conference, held in San Francisco, California, USA, from May 16 th –21 st, 2025 According to the current Global ...

Vascular dysfunction has been described as worsening in Chronic Obstructive Pulmonary Disease (COPD), but there is a lack of knowledge regarding severe patients. This retrospective cross-sectional ...

new video loaded: How Charismatic Can a Moderate Politician Be? transcript “I think Americans — those who are not spending all their lives on social media — are so tired of the temperature of our ...

All dose groups demonstrated good safety and tolerability versus placebo, with similar adverse event (AE) incidence (70% vs. 85%). At the recommended Phase IIb dose (RP2D), the annualized rate of ...